Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Ownership structure
    • Financial calendar & Events
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Remuneration

Press releases

All press releases Regulatory

Regulatory press release 2022-02-07

Xspray Pharma appoints Global Head of Marketing and Sales

Regulatory press release 2022-01-13

FDA allows review of application for market approval for Xspray Pharma’s Dasynoc™

Regulatory press release 2021-11-30

Number of shares and votes in Xspray Pharma

Press release 2021-11-18

Xspray Pharma submits application for market approval to FDA for its product candidate Dasynoc

Press release 2021-11-15

Xspray Pharma strengthens the organization with IR and Communications function

Regulatory press release 2021-11-08

Xspray Pharma completes a directed new share issue to Flerie Invest, raising approximately SEK 100 million

Regulatory press release 2021-10-26

Xspray Pharma publishes interim report Q3, January – September 2021

Regulatory press release 2021-10-25

Xspray Pharma brings forward publication of the Q3 interim report

Regulatory press release 2021-10-15

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2022

Regulatory press release 2021-10-13

Xspray Pharma has obtained results from bioequivalence studies with HyNap-Dasa ANDA and decides to focus on its improved dasatinib product, Dasynoc™

Show more

IR contact

Kerstin Hasselgren, IRO / Senior Adviser

+46 (0)70 311 16 83

info@xspray.com

Subscribe

  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
  • This field is for validation purposes and should be left unchanged.
Xspray-logo-white

Xspray Pharma AB Scheeles väg 2 171 65 Solna

+46 (0)8 730 37 00 info@xspraypharma.com

We use cookie to give you the best experience of our site. If you continue to use this website we will assume you agree. Read more about our Privacy policy.I agree